GHRS Key Statistics, Chart & Performance
The current stock price of GHRS is 16.61 USD. In the past month the price increased by 28.57%. In the past year, price increased by 89.58%.
GHRS Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to GHRS. When comparing the yearly performance of all stocks, GHRS is one of the better performing stocks in the market, outperforming 93.2% of all stocks.
GHRS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GHRS. GHRS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
GHRS Financial Highlights
Over the last trailing twelve months GHRS reported a non-GAAP Earnings per Share(EPS) of -0.74. The EPS increased by 6.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.21% | ||
| ROE | -14.73% | ||
| Debt/Equity | 0 |
GHRS Forecast & Estimates
15 analysts have analysed GHRS and the average price target is 33.28 USD. This implies a price increase of 100.35% is expected in the next year compared to the current price of 16.61.
GHRS Ownership
GHRS Latest News, Press Relases and Analysis
About GHRS
Company Profile
GH Research Plc operates as a holding company, which engages in the provision of biopharmaceutical products and services. The company is headquartered in Dublin, Leinster and currently employs 50 full-time employees. The company went IPO on 2021-06-25. The firm is engaged in offering treatment for psychiatric and neurological disorders. The firm's pipeline includes GH001, GH002 and GH003. The firm focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
Company Info
GH RESEARCH PLC
Joshua Dawson House, Dawson Street
DUBLIN LEINSTER IE
CEO: Theis Terwey
Employees: 50
Phone: 35314378334
GH RESEARCH PLC / GHRS FAQ
What does GH RESEARCH PLC do?
GH Research Plc operates as a holding company, which engages in the provision of biopharmaceutical products and services. The company is headquartered in Dublin, Leinster and currently employs 50 full-time employees. The company went IPO on 2021-06-25. The firm is engaged in offering treatment for psychiatric and neurological disorders. The firm's pipeline includes GH001, GH002 and GH003. The firm focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
Can you provide the latest stock price for GH RESEARCH PLC?
The current stock price of GHRS is 16.61 USD. The price decreased by -0.78% in the last trading session.
Does GH RESEARCH PLC pay dividends?
GHRS does not pay a dividend.
What is the ChartMill rating of GH RESEARCH PLC stock?
GHRS has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for GHRS stock?
15 analysts have analysed GHRS and the average price target is 33.28 USD. This implies a price increase of 100.35% is expected in the next year compared to the current price of 16.61.
Should I buy GHRS stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GHRS.